Cantor Fitzgerald’s LAVA Therapeutics LVTX Stock Holding History

Cantor Fitzgerald’s Portfolio LVTX Stock Details LVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-53,299	Closed	-$88.5K	–	612
2023 Q1	$88.5K	Buy	+53,299	New	+$149K	﹤0.01%	573

Other funds holding LVTX

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Bruce & Co Chicago, Illinois $369M AUM 50.95% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Cantor Fitzgerald's LVTX Position: Q2 2023 in Review

Cantor Fitzgerald sold out of LAVA Therapeutics (LVTX) in Q2 2023, closing a stake of 53,299 shares — an estimated $88.5K sold.

Cantor Fitzgerald first reported a position in LVTX in Q1 2023 and held it in 1 quarter. The position peaked at $88.5K in Q1 2023. 15 funds tracked by Wall St. Rank hold LVTX as of Q2 2023.

Cantor Fitzgerald reported no remaining LAVA Therapeutics position as of Q2 2023 after selling out during the quarter.
Cantor Fitzgerald sold 53,299 LAVA Therapeutics shares in Q2 2023, an estimated $88.5K.
Cantor Fitzgerald first reported a position in LAVA Therapeutics in Q1 2023 and held it in 1 quarter.
Cantor Fitzgerald's LAVA Therapeutics position peaked at $88.5K in Q1 2023.
15 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q2 2023.

Based on Cantor Fitzgerald's 13F filing for Q2 2023, filed 14 Aug 2023.